Gapping up
In reaction to strong earnings/guidance: DPW +15.5%
M&A news:
In reaction to strong earnings/guidance: DPW +15.5%
M&A news:
- ELOS +5.2% (confirms agreement to be acquired by Apax Partners for $11/share in cash)
- SCMP +0.9% (acquires privately-held Vtesse for upfront consideration of $200 mln)
Select Macau gaming related names showing strength after Macau gaming bureau reported 18% YoY increased in revs for March:
- MPEL +2.5%, WYNN +2.5%, LVS +1.6%, MGM +0.9%
Other news:
- NVCR +58.6% (announced results from the second cohort of its phase 2 pilot PANOVA trial and results from its phase 2 pilot INNOVATE trial)
- STDY +42.2% (Cardiome Pharma announces that its partner, SteadyMed Therapeutics (STDY), announced a favourable outcome of its Inter Partes Review by the Patent Trial and Appeal Board of the United States Patent Trademark Office)
- APOP +17.8% (receives a formal notice of Intention to Grant for a patent covering a key method of treatment from the EPO)
- IDXG +16.3% (European Patent Office granted it a Patent for use of microRNAs for distinguishing benign from malignant thyroid neoplasms)
- DVAX +16% (FDA has informed the co that the Vaccines and Related Biological Products Advisory Committee will review HEPLISAV-B at its meeting scheduled for July 28), INFI +13.6% (presents updated Phase 1 Data for IPI-549; was well tolerated as a monotherapy and in combination with Opdivo)
- AVEO +11.9% (receives a $500K milestone payment from CANbridge Life Sciences)
- ONCS +9.4% (preclinical data demonstrating the latest developments of its gene delivery platform in a murine melanoma model)
- EBIO +9.1% (reports new preclinical data with VB4-845)
- ARTX +8.5% (receives a sole source follow-on contract to support the U.S. Army's Virtual Clearance Training Suite program)
- BVXV +8.3% (continued strength)
- PPHM +7.7% (presentation of preclinical study results; latest findings from ongoing collaboration with memorial sloan kettering )
- SRRA +7.2% (reports that preclinical results for its Chk1 inhibitor, SRA737)
- KITE +5.1% (reports primary analysis of ZUMA-1 for its lead CAR-T candidate)
- BOLD +5% (FDA has cleared the investigational new drug application for AT132)
- BCRX +4.8% (Mundipharma has obtained regulatory approval of Mundesine )
- CRME +4% (announces that its partner, SteadyMed Therapeutics (STDY), announced a favourable outcome of its Inter Partes Review by the Patent Trial and Appeal Board of the United States Patent Trademark Office)
- ATRS +3.9% (presented data from phase 3 study of subcutaneous testosterone enanthate delivered through the QuickShot auto injector)
- TSLA +3.6% (reports Q1 deliveries of over 25K vehicles, up 69% YoY)
- VSAR +3% (new data on somavaratan in pediatric and adult GHD)
- AVXL +2.8% (presentation of new mechanism of action data related to ANAVEX compounds targeting the sigma-1 receptor)
- ZIOP +2.5% (Intrexon, ZIOPHARM (ZIOP), and Merck kGaA (MKGAY) update on the development of next-generation chimeric antigen receptor T cell therapy for cancer as part of their strategic collaboration and license agreement)
Analyst comments:
- GVA +3.6% (upgraded to Buy from Neutral at Goldman)
- CYRX +1.7% (initiated with a Buy at Needham)
- HUN +1.6% (upgraded to Buy from Neutral at Citigroup)
- FMC +1.6% (upgraded to Positive from Neutral at Susquehanna)
- BBRY +1.5% (upgraded to Outperform from Neutral at Macquarie)